Other News To Note
Monday, November 5, 2012
Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it will receive a $1.25 million contingent payment from Pfizer Inc., of New York, triggered by Pfizer's decision to advance the antiscarring therapy EXC 001 into a Phase II study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.